Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cassidy Carr

Clinical Nurse Specialist, Psychiatric/Mental Health Des Moines, IA Nurse Practitioner

NPI 1871052472 CMS profile 11042106

1250 E 9Th St, Des Moines, IA 50316

Open in the dashboard

General payments

$3,801

255 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cassidy Carr of Des Moines, IA is reported in the CMS Open Payments database as having received $3,801 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 1
2024 General $111 1
2023 General $805 49
2022 General $1,499 114
2021 General $1,263 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cassidy Carr
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Cassidy Carr were reported at $122. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Cassidy Carr Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,263 $153 $44–$540 $132
2022 $1,499 $207 $60–$748 $149
2023 $805 $197 $55–$898 $160
2024 $111 $189 $49–$804 $164
2025 $122 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $587 31 payments
  2. Teva Pharmaceuticals USA, Inc. $562 23 payments
  3. Janssen Pharmaceuticals, Inc $493 34 payments
  4. ITI, Inc. $457 34 payments
  5. Neurocrine Biosciences, Inc. $448 40 payments
  6. AbbVie, Inc. $353 31 payments
  7. Lundbeck LLC $169 11 payments
  8. Vanda Pharmaceuticals Inc. $152 9 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $131 8 payments
  10. Otsuka America Pharmaceutical, Inc. $115 8 payments
  11. Other $334 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,551 252 payments
  2. Education $250 3 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $482 23 payments
  2. INVEGA SUSTENNA $482 32 payments
  3. ARISTADA Cns $465 30 payments
  4. ARISTADA Cns $465 30 payments
  5. CAPLYTA $457 34 payments
  6. LYBALVI Cns $384 17 payments
  7. ARISTADA INITIO $368 24 payments
  8. VRAYLAR $353 31 payments
  9. INVEGA TRINZA $334 28 payments
  10. AUSTEDO $290 17 payments
  11. Other $2,274 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

289

Median for Nurse Practitioner: 389

Drug cost

$24,372

Median for Nurse Practitioner: $21,885

Branded share of claims

9.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $20,294
Aripiprazole Generic 20 $1,338
Hydroxyzine Hcl Generic 25 $554
Divalproex Sodium Er Divalproex Sodium Brand 13 $450
Gabapentin Generic 21 $244
Olanzapine Generic 22 $233
Quetiapine Fumarate Generic 28 $224
Trazodone Hcl Generic 31 $203
Propranolol Hcl Generic 13 $141
Buspirone Hcl Generic 20 $140

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$2,261

Medicare's payments for the services billed

Medicare patients

36

Average age 61

Services billed

41

19 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 67%
High blood pressure 58%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record